세계의 차세대 시퀀싱(NGS) 시장 예측(-2029년) : 제품 유형별, 기술별, 워크플로우별, 서비스별, 용도별

The next-generation sequencing market is expected to reach USD 22.38 billion in 2029 from USD 13.28 billion in 2024, at a CAGR of 11.0% during the forecast period.

The increasing adoption of NGS in areas like oncology, infectious diseases, reproductive health, metagenomics, and personalized medicine is a major growth driver. Moreover, improved bioinformatics tools for data analysis and interpretation are enhancing the usability of NGS, driving its widespread adoption.

"The consumables segment accounted for the largest share by products segment in the NGS market in 2023"

The NGS products market is divided into consumables, platforms, and bioinformatics tools. The consumables holds the largest share of the market in 2023. The consumables is the segment with the largest share in products. The consumables segment dominates the product type category of the NGS market. These include reagents, library preparation kits, sequencing flow cells, and sample preparation kits, which are consumed in large volumes across diverse applications. The ongoing need for high-quality consumables ensures a steady demand, unlike instruments that represent one-time purchases. Additionally, the increasing adoption of targeted sequencing and custom panels drives the demand for specialized consumables tailored for specific research and clinical applications. The growing number of NGS users, coupled with advancements in sequencing chemistries, has further increased the reliance on consumables to optimize workflows and improve data quality.

"The academic & research institutes segment accounted for the largest share by services end-user segment in the NGS market in 2023"

The NGS services market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & clinical laboratories, and other end users. The academic & research institutes are the segment with the largest share in the end-user segment in 2023. The large share of academic & research institutes is due to these institutions benefit from substantial government and private funding for research projects, enabling significant investments in NGS products, including instruments and consumables. However, the pharmaceutical & biotechnological companies accounted for the second largest share in the segment.

"The Asia Pacific region is growing at the highest CAGR in the NGS market from 2024 to 2029."

The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the large scale of population genomics projects, and the rising demand for precision medicines is supporting the growth. Further, the rising prevalence of rare and genetic diseases is attributed to the aging population of countries such as Japan, and China. This is supporting the adoption of sequencing technologies in healthcare management and treatment driving the market growth.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%,
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.

List of Companies Profiled in the Report:

• Illumina, Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Danaher Corporation (US)
• QIAGEN (Netherlands)
• Agilent Technologies, Inc. (US)
• Revvity (US)
• Eurofins Scientific (Luxembourg)
• PacBio (US)
• Oxford Nanopore Technologies plc. (UK)
• Takara Bio Inc. (Japan)
• BGI Group (China)
• Merck KGaA (Germany)
• BD (US)
• 10X Genomics (US)
• New England Biolabs (US)
• Promega Corporation (US)
• Novogene Co., Ltd. (China)
• LGC Limited (UK)
• WuXi Biologics (China)
• MGI Tech Co. Ltd. (China)
• Tecan Trading AG (Switzerland)
• Twist Biosciences (US)
• Azenta US, Inc. (US)
• GenScript (US)
• SD Biosensor, Inc. (South Korea)
• Fulgent Genetics (US)
• Hamilton Company (US)
• Zymo Research Corporation (US)
• NeoGenomics Laboratories (US)
• Psomagen (US)

Research Coverage:

This research report categorizes the NGS market by offerings (products and services), products by type (consumables, platforms, bioinformatics tools), consumables (library preparation kits & reagents, sequencing kits & reagents, and other consumables), platforms (sequencing platforms, library preparation platforms), bioinformatics tools (data analysis software & workbenches, data visualization tools, and other tools), platforms by technology (sequencing by synthesis, ion semiconductor sequencing, single-molecule real time sequencing, nanopore sequencing, and other sequencing technologies), products by workflow (presequencing, sequencing , and data analysis), products by end user (academic and research institutes, pharmaceutical and biotechnology companies, clinical & diagnostics laboratories, and other end users), services by type (sequencing services, presequencing services, bioinformatics and data analysis services, and services for NGS platforms), presequencing services by type (library preparation & target enrichment, sample preparation, and quality control), sequencing services by type (exome & targeted resequencing and custom panels, rna sequencing, de novo sequencing, chip sequencing, whole genome sequencing, methyl sequencing, and other sequencing services), bioinformatics & data analysis services by type (data analysis services, data visualization and interpretation, data storage and management services), services by workflow (presequencing services, sequencing services, and data analysis services), servuces by end user (academics and research institutes, pharmaceutical and biotechnology companies, hospitals and clinical laboratories, other end users), application (drug discovery & development, diagnostics, agriculture and animal research, and other applications), diagnostic applications (cancer diagnostics, infectious disease diagnostics, reproductive health diagnostics, and other diagnostic applications), drug discovery & development application (pharmacogenomics, and other drug discovery & development applications), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the NGS market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as product & service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the NGS market. Competitive analysis of top players and upcoming startups in the NGS market ecosystem is covered in this report

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall NGS market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Advancements in sequencing platforms, Rising clinical applications of sequencing, Growing demand for precision medicine, Declining sequencing cost), restraints (Data analysis complexity, High initial capital investment), opportunities (Integration of AI and ML, adoption of long-read sequencing technologies, emphasis on multiomics integration), and challenges (Standardization issues) influencing the growth of the market.

• Product Development/Innovation: Detailed insights on newly launched products/services of the NGS market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the genomics market
• Competitive Assessment: Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), QIAGEN (Netherlands), Agilent Technologies, Inc. (US), Revvity (US), Eurofins Scientific (Luxembourg), PacBio (US), Oxford Nanopore Technologies plc. (UK), Takara Bio Inc. (Japan), BGI Group (China), Merck KGaA (Germany), BD (US), 10X Genomics (US), New England Biolabs (US), Promega Corporation (US), Novogene Co., Ltd. (China), LGC Limited (UK), WuXi Biologics (China), MGI Tech Co. Ltd. (China), Tecan Trading AG (Switzerland), Twist Biosciences (US), Azenta US, Inc. (US), GenScript (US), SD Biosensor, Inc. (South Korea), Fulgent Genetics (US), Hamilton Company (US), Zymo Research Corporation (US), NeoGenomics Laboratories (US), and Psomagen (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SEGMENTATION
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 GLOBAL MARKET ESTIMATION
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 NGS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: NGS MARKET, BY COUNTRY AND PRODUCT TYPE
• 4.3 NGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 NGS PRODUCTS MARKET SHARE, BY END USER, 2023

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Advancements in sequencing platforms
      • 5.2.1.1.1 Revio
      • 5.2.1.1.2 PromethION 2 Solo
      • 5.2.1.1.3 Ion Torrent Genexus Dx
    • 5.2.1.2 Rising clinical applications of sequencing
    • 5.2.1.3 Growing demand for precision medicine
    • 5.2.1.4 Declining costs of sequencing
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Data analysis complexity
    • 5.2.2.2 High capital investment and expenses
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Integration of AI and ML
    • 5.2.3.2 Adoption of long-read sequencing technologies
    • 5.2.3.3 Emphasis on multiomics integration
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Standardization issues
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 REGULATORY LANDSCAPE
  • 5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.4.2 REGULATORY FRAMEWORK
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 TECHNOLOGY ANALYSIS
  • 5.6.1 KEY TECHNOLOGIES
    • 5.6.1.1 Sequencing by synthesis
    • 5.6.1.2 Single-molecule real-time sequencing
    • 5.6.1.3 Nanopore sequencing
    • 5.6.1.4 Ion semiconductor sequencing
  • 5.6.2 COMPLEMENTARY TECHNOLOGIES
    • 5.6.2.1 Automated sample preparation systems
    • 5.6.2.2 Bioinformatics and data analysis platforms
    • 5.6.2.3 CRISPR-based targeted sequencing
    • 5.6.2.4 Multiplex PCR
  • 5.6.3 ADJACENT TECHNOLOGIES
    • 5.6.3.1 Single-cell sequencing technology
    • 5.6.3.2 Multi-omics integration
    • 5.6.3.3 Spatial genomics and transcriptomics
    • 5.6.3.4 Gene editing technologies
• 5.7 PRICING ANALYSIS
  • 5.7.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
    • 5.7.1.1 Average selling price trend of instruments, by key player, 2018-2023
    • 5.7.1.2 Average selling price trend of consumables, by key player, 2022-2024
    • 5.7.1.3 Average selling price of services, by key player, 2024
  • 5.7.2 AVERAGE SELLING PRICE, BY REGION
• 5.8 PATENT ANALYSIS
• 5.9 SUPPLY CHAIN ANALYSIS
• 5.10 ECOSYSTEM ANALYSIS
• 5.11 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12.2 BARGAINING POWER OF SUPPLIERS
  • 5.12.3 BARGAINING POWER OF BUYERS
  • 5.12.4 THREAT OF SUBSTITUTES
  • 5.12.5 THREAT OF NEW ENTRANTS
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 KEY BUYING CRITERIA, BY END USER
• 5.14 INVESTMENT AND FUNDING SCENARIO
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 CASE STUDY 1: IDENTIFYING TANDEM REPEAT LINKED TO ALS USING SMRT SEQUENCING
  • 5.15.2 CASE STUDY 2: LONG-READ WHOLE-GENOME SEQUENCING AT CHILDREN'S MERCY KANSAS CITY
  • 5.15.3 CASE STUDY 3: SNP ARRAY IDENTIFIED INHERITED GENETIC DISORDER CONTRIBUTING TO IVF FAILURES
• 5.16 TRADE ANALYSIS
  • 5.16.1 IMPORT DATA
  • 5.16.2 EXPORT DATA
• 5.17 IMPACT OF AI ON NEXT-GENERATION SEQUENCING MARKET

6 NEXT-GENERATION SEQUENCING MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 PRODUCTS
  • 6.2.1 WIDE DEMAND FOR CONSUMABLES AND TECHNOLOGICAL ADVANCEMENTS TO PROPEL MARKET
• 6.3 SERVICES
  • 6.3.1 SHIFT TOWARD SERVICE-BASED MODELS TO DRIVE MARKET

7 NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 CONSUMABLES
  • 7.2.1 LIBRARY PREPARATION & AND REAGENTS
    • 7.2.1.1 Strong demand and growing applications to ensure market growth
  • 7.2.2 SEQUENCING KITS & REAGENTS
    • 7.2.2.1 Technological advancements to support market growth
  • 7.2.3 OTHER CONSUMABLES
• 7.3 PLATFORMS
  • 7.3.1 SEQUENCING PLATFORMS
    • 7.3.1.1 Illumina
      • 7.3.1.1.1 NovaSeq
        • 7.3.1.1.1.1 Flexibility and automated data processing to reduce time and labor cost
      • 7.3.1.1.2 NextSeq
        • 7.3.1.1.2.1 Introduction of advanced systems to affect demand for NextSeq
      • 7.3.1.1.3 MiSeq
        • 7.3.1.1.3.1 Small size and rapid operations to drive adoption in clinical labs
      • 7.3.1.1.4 MiniSeq
        • 7.3.1.1.4.1 Cross-application flexibility and small footprint to propel demand
      • 7.3.1.1.5 iSeq 100
        • 7.3.1.1.5.1 High accuracy and lower costs to support market growth
    • 7.3.1.2 Thermo Fisher Scientific
    • 7.3.1.3 PacBio
    • 7.3.1.4 Oxford Nanopore Technologies
    • 7.3.1.5 Other sequencing platforms
  • 7.3.2 LIBRARY PREPARATION PLATFORMS
    • 7.3.2.1 Rising demand for sequencing in clinical applications to drive market
• 7.4 BIOINFORMATICS TOOLS
  • 7.4.1 DATA ANALYSIS SOFTWARE & WORKBENCHES
    • 7.4.1.1 Demand for genome analysis in clinical diagnostics to support market growth
  • 7.4.2 DATA VISUALIZATION TOOLS
    • 7.4.2.1 Rising demand for sequencing-based research to support market growth
  • 7.4.3 OTHER BIOINFORMATICS TOOLS

8 NEXT-GENERATION SEQUENCING PLATFORMS MARKET, BY TECHNOLOGY

• 8.1 INTRODUCTION
• 8.2 SEQUENCING BY SYNTHESIS
  • 8.2.1 HIGH, RAPID PRODUCTION OF BASE PAIRS TO SUPPORT ADOPTION
• 8.3 ION SEMICONDUCTOR SEQUENCING
  • 8.3.1 SIMPLER WORKFLOW AND COST-EFFECTIVENESS TO SUPPORT MARKET GROWTH
• 8.4 SMRT SEQUENCING
  • 8.4.1 RAPID RESULTS AND LOWER SEQUENCING COSTS TO DRIVE MARKET
• 8.5 NANOPORE SEQUENCING
  • 8.5.1 DIRECT RNA SEQUENCING CAPABILITIES TO PROPEL DEMAND
• 8.6 OTHER SEQUENCING TECHNOLOGIES

9 NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY WORKFLOW

• 9.1 INTRODUCTION
• 9.2 SEQUENCING
  • 9.2.1 DIRECT DETECTION OF DNA MODIFICATIONS DURING SEQUENCING TO DRIVE MARKET
• 9.3 PRESEQUENCING
  • 9.3.1 DEVELOPMENT OF ADVANCED LIBRARY PREPARATION SOLUTIONS TO BOOST MARKET GROWTH
• 9.4 DATA ANALYSIS
  • 9.4.1 DEVELOPMENT OF ADVANCED BIOINFORMATICS SOLUTIONS TO DRIVE MARKET

10 NEXT-GENERATION SEQUENCING PRODUCTS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 ACADEMIC & RESEARCH INSTITUTES
  • 10.2.1 RISING RESEARCH INTENSITY FOR GENOME RESEARCH AMONG INSTITUTES TO SUPPORT MARKET GROWTH
• 10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.3.1 RISING DEMAND FOR COMPREHENSIVE SEQUENCING DATA IN GENETIC RESEARCH TO DRIVE MARKET
• 10.4 CLINICAL & DIAGNOSTIC LABORATORIES
  • 10.4.1 INCREASED APPLICATIONS IN DISEASE DIAGNOSTICS AND TREATMENT TO DRIVE MARKET GROWTH
• 10.5 OTHER END USERS

11 NEXT-GENERATION SEQUENCING SERVICES MARKET, BY TYPE

• 11.1 INTRODUCTION
• 11.2 SEQUENCING SERVICES
  • 11.2.1 EXOME & TARGETED RESEQUENCING AND CUSTOM PANELS
    • 11.2.1.1 Development of technologically advanced NGS products and services to propel growth
  • 11.2.2 RNA SEQUENCING
    • 11.2.2.1 Technological advancements to support market growth
  • 11.2.3 DE NOVO SEQUENCING
    • 11.2.3.1 Rising awareness of De Novo sequencing to drive market
  • 11.2.4 CHIP SEQUENCING
    • 11.2.4.1 Increased demand for ChIP sequencing to propel growth
  • 11.2.5 WHOLE-GENOME SEQUENCING
    • 11.2.5.1 Reduced cost of WGS to support market growth
  • 11.2.6 METHYL SEQUENCING
    • 11.2.6.1 Increased demand for methyl sequencing in cancer research to support market growth
  • 11.2.7 OTHER SEQUENCING SERVICES
• 11.3 PRESEQUENCING SERVICES
  • 11.3.1 LIBRARY PREPARATION & TARGET ENRICHMENT
    • 11.3.1.1 Development of advanced library preparation solutions to drive market
  • 11.3.2 SAMPLE PREPARATION
    • 11.3.2.1 Development of automated sample preparation solutions to boost growth
  • 11.3.3 QUALITY CONTROL
    • 11.3.3.1 Importance of quality control in NGS workflow to boost growth
• 11.4 BIOINFORMATICS & DATA ANALYSIS SERVICES
  • 11.4.1 DATA ANALYSIS
    • 11.4.1.1 Increasing demand for genome analysis for clinical diagnosis to drive market
  • 11.4.2 DATA VISUALIZATION & INTERPRETATION
    • 11.4.2.1 Rising demand for sequencing-based research to support market growth
  • 11.4.3 DATA STORAGE & MANAGEMENT
    • 11.4.3.1 Demand for effective data management to propel market growth
• 11.5 NGS PLATFORM SERVICES
  • 11.5.1 NEED FOR COMPLIANCE AND MINIMIZING PLATFORM DOWNTIME TO DRIVE ADOPTION

12 NEXT-GENERATION SEQUENCING SERVICES MARKET, BY WORKFLOW

• 12.1 INTRODUCTION
• 12.2 SEQUENCING
  • 12.2.1 RISING DEMAND FOR SEQUENCING SERVICES AND APPLICATIONS IN CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH
• 12.3 PRESEQUENCING SERVICES
  • 12.3.1 CUSTOM DEVELOPMENT OF SAMPLES FOR SEQUENCING TO BOOST MARKET GROWTH
• 12.4 DATA ANALYSIS SERVICES
  • 12.4.1 RISING DEMAND FOR ADVANCED RESEARCH TO DRIVE MARKET

13 NEXT-GENERATION SEQUENCING SERVICES MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 ACADEMIC & RESEARCH INSTITUTES
  • 13.2.1 RISING RESEARCH INTENSITY TO SUPPORT MARKET GROWTH
• 13.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 13.3.1 RISING DEMAND FOR COMPREHENSIVE GENETIC DATA TO DRIVE GROWTH
• 13.4 HOSPITALS & CLINICAL LABORATORIES
  • 13.4.1 INCREASED APPLICATION IN DISEASE DIAGNOSTICS AND TREATMENT TO DRIVE MARKET GROWTH
• 13.5 OTHER END USERS

14 NEXT-GENERATION SEQUENCING MARKET, BY APPLICATION

• 14.1 INTRODUCTION
• 14.2 DIAGNOSTICS
  • 14.2.1 CANCER DIAGNOSTICS
    • 14.2.1.1 Rising demand for targeted therapies to drive market
  • 14.2.2 INFECTIOUS DISEASE DIAGNOSTICS
    • 14.2.2.1 Rising demand for comprehensive genomic data in clinical diagnostics to propel adoption
  • 14.2.3 REPRODUCTIVE HEALTH DIAGNOSTICS
    • 14.2.3.1 Focus on genetic disease diagnostics to drive growth
  • 14.2.4 OTHER DIAGNOSTIC APPLICATIONS
• 14.3 DRUG DISCOVERY & DEVELOPMENT
  • 14.3.1 PHARMACOGENOMICS
    • 14.3.1.1 Rising use of NGS for understanding genomic variants in humans to drive growth
  • 14.3.2 OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS
• 14.4 AGRICULTURE & ANIMAL RESEARCH
  • 14.4.1 EMPHASIS ON IMPROVING CROP PRODUCTIVITY TO DRIVE ADOPTION OF NGS
• 14.5 OTHER APPLICATIONS

15 NEXT-GENERATION SEQUENCING MARKET, BY REGION

• 15.1 INTRODUCTION
• 15.2 NORTH AMERICA
  • 15.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 15.2.2 US
    • 15.2.2.1 US expected to dominate market in North America
  • 15.2.3 CANADA
    • 15.2.3.1 Increasing government initiatives in sequencing research to boost market growth
• 15.3 EUROPE
  • 15.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 15.3.2 GERMANY
    • 15.3.2.1 Germany to dominate European NGS market
  • 15.3.3 UK
    • 15.3.3.1 Strategic initiatives and funding for genomics research to support market growth
  • 15.3.4 FRANCE
    • 15.3.4.1 Increasing government investment in genomics research to drive growth
  • 15.3.5 ITALY
    • 15.3.5.1 Favorable funding scenario to drive adoption of advanced sequencing technology
  • 15.3.6 SPAIN
    • 15.3.6.1 Growing focus on advancements in personalized medicine to support market growth
  • 15.3.7 NETHERLANDS
    • 15.3.7.1 Well-established research infrastructure to sustain demand for NGS
  • 15.3.8 REST OF EUROPE
• 15.4 ASIA PACIFIC
  • 15.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 15.4.2 CHINA
    • 15.4.2.1 China to dominate Asia Pacific market during forecast period
  • 15.4.3 JAPAN
    • 15.4.3.1 Rising number of collaborations in NGS to drive market
  • 15.4.4 INDIA
    • 15.4.4.1 Government and private initiatives for genomics projects to propel market
  • 15.4.5 AUSTRALIA
    • 15.4.5.1 Increased genetic research in Australia to support market growth
  • 15.4.6 SOUTH KOREA
    • 15.4.6.1 Demand for advanced sequencing technologies to support market growth in South Korea
  • 15.4.7 REST OF ASIA PACIFIC
• 15.5 LATIN AMERICA
  • 15.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 15.5.2 BRAZIL
    • 15.5.2.1 Increased government investments in genomics advancements to drive market
  • 15.5.3 MEXICO
    • 15.5.3.1 Rising demand for chronic disease treatment to support market growth in Mexico
  • 15.5.4 REST OF LATIN AMERICA
• 15.6 MIDDLE EAST
  • 15.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
  • 15.6.2 GCC COUNTRIES
    • 15.6.2.1 Saudi Arabia
      • 15.6.2.1.1 Growing healthcare expenditure in Saudi Arabia to boost market growth
    • 15.6.2.2 UAE
      • 15.6.2.2.1 Collaborations to advance genome sequencing and market growth
    • 15.6.2.3 Rest of GCC Countries
  • 15.6.3 REST OF MIDDLE EAST
• 15.7 AFRICA
  • 15.7.1 GROWING FOCUS ON PRECISION MEDICINE TO PROPEL MARKET
  • 15.7.2 AFRICA: MACROECONOMIC OUTLOOK

16 COMPETITIVE LANDSCAPE

• 16.1 INTRODUCTION
• 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NGS MARKET
• 16.3 REVENUE ANALYSIS, 2019-2023
• 16.4 MARKET SHARE ANALYSIS, 2023
• 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 16.5.1 STARS
  • 16.5.2 EMERGING LEADERS
  • 16.5.3 PERVASIVE PLAYERS
  • 16.5.4 PARTICIPANTS
  • 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 16.5.5.1 Company footprint
    • 16.5.5.2 Region footprint
    • 16.5.5.3 Offering footprint
    • 16.5.5.4 Application footprint
    • 16.5.5.5 Technology footprint
• 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 16.6.1 PROGRESSIVE COMPANIES
  • 16.6.2 RESPONSIVE COMPANIES
  • 16.6.3 DYNAMIC COMPANIES
  • 16.6.4 STARTING BLOCKS
  • 16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 16.6.5.1 Detailed list of key startups/SMEs
    • 16.6.5.2 Competitive benchmarking of startups/SMEs
• 16.7 VALUATION & FINANCIAL METRICS
  • 16.7.1 FINANCIAL METRICS
  • 16.7.2 COMPANY VALUATION
• 16.8 BRAND/PRODUCT COMPARISON
• 16.9 COMPETITIVE SCENARIO
  • 16.9.1 DEALS
  • 16.9.2 EXPANSIONS

17 COMPANY PROFILES

• 17.1 KEY PLAYERS
  • 17.1.1 ILLUMINA, INC.
    • 17.1.1.1 Business overview
    • 17.1.1.2 Products/services offered
    • 17.1.1.3 Recent developments
      • 17.1.1.3.1 Product launches
      • 17.1.1.3.2 Deals
      • 17.1.1.3.3 Expansions
    • 17.1.1.4 MnM view
      • 17.1.1.4.1 Key strengths
      • 17.1.1.4.2 Strategic choices
      • 17.1.1.4.3 Weaknesses and competitive threats
  • 17.1.2 THERMO FISHER SCIENTIFIC INC.
    • 17.1.2.1 Business overview
    • 17.1.2.2 Products/services offered
    • 17.1.2.3 Recent developments
      • 17.1.2.3.1 Product launches, approvals, and enhancements
      • 17.1.2.3.2 Deals
      • 17.1.2.3.3 Expansions
    • 17.1.2.4 MnM view
      • 17.1.2.4.1 Key strengths
      • 17.1.2.4.2 Strategic choices
      • 17.1.2.4.3 Weaknesses and competitive threats
  • 17.1.3 AGILENT TECHNOLOGIES, INC.
    • 17.1.3.1 Business overview
    • 17.1.3.2 Products/services offered
    • 17.1.3.3 Recent developments
      • 17.1.3.3.1 Deals
      • 17.1.3.3.2 Expansions
    • 17.1.3.4 MnM view
      • 17.1.3.4.1 Key strengths
      • 17.1.3.4.2 Strategic choices
      • 17.1.3.4.3 Weaknesses and competitive threats
  • 17.1.4 F. HOFFMANN-LA ROCHE LTD.
    • 17.1.4.1 Business overview
    • 17.1.4.2 Products/services offered
    • 17.1.4.3 Recent developments
      • 17.1.4.3.1 Product launches
      • 17.1.4.3.2 Deals
  • 17.1.5 DANAHER CORPORATION
    • 17.1.5.1 Business overview
    • 17.1.5.2 Products/services offered
    • 17.1.5.3 Recent developments
      • 17.1.5.3.1 Product launches & approvals
      • 17.1.5.3.2 Deals
      • 17.1.5.3.3 Expansions
  • 17.1.6 QIAGEN
    • 17.1.6.1 Business overview
    • 17.1.6.2 Products/services offered
    • 17.1.6.3 Recent developments
      • 17.1.6.3.1 Deals
      • 17.1.6.3.2 Expansions
  • 17.1.7 REVVITY
    • 17.1.7.1 Business overview
    • 17.1.7.2 Products/services offered
    • 17.1.7.3 Recent developments
      • 17.1.7.3.1 Product launches
      • 17.1.7.3.2 Deals
      • 17.1.7.3.3 Expansions
  • 17.1.8 EUROFINS SCIENTIFIC
    • 17.1.8.1 Business overview
    • 17.1.8.2 Products/services offered
    • 17.1.8.3 Recent developments
      • 17.1.8.3.1 Service launches
      • 17.1.8.3.2 Deals
  • 17.1.9 PACBIO
    • 17.1.9.1 Business overview
    • 17.1.9.2 Products/services offered
    • 17.1.9.3 Recent developments
      • 17.1.9.3.1 Product launches
      • 17.1.9.3.2 Deals
      • 17.1.9.3.3 Expansions
      • 17.1.9.3.4 Other developments
  • 17.1.10 OXFORD NANOPORE TECHNOLOGIES PLC.
    • 17.1.10.1 Business overview
    • 17.1.10.2 Products/services offered
    • 17.1.10.3 Recent developments
      • 17.1.10.3.1 Product launches
      • 17.1.10.3.2 Deals
  • 17.1.11 TAKARA BIO INC.
    • 17.1.11.1 Business overview
    • 17.1.11.2 Products/services offered
    • 17.1.11.3 Recent developments
      • 17.1.11.3.1 Product launches
      • 17.1.11.3.2 Deals
  • 17.1.12 BGI GROUP
    • 17.1.12.1 Business overview
    • 17.1.12.2 Products/services offered
    • 17.1.12.3 Recent developments
      • 17.1.12.3.1 Product & service launches and approvals
      • 17.1.12.3.2 Deals
      • 17.1.12.3.3 Other developments
  • 17.1.13 BD
    • 17.1.13.1 Business overview
    • 17.1.13.2 Products/services offered
    • 17.1.13.3 Recent developments
      • 17.1.13.3.1 Product & service launches
      • 17.1.13.3.2 Deals
  • 17.1.14 10X GENOMICS
    • 17.1.14.1 Business overview
    • 17.1.14.2 Products/services offered
    • 17.1.14.3 Recent developments
      • 17.1.14.3.1 Product launches
  • 17.1.15 PROMEGA CORPORATION
    • 17.1.15.1 Business overview
    • 17.1.15.2 Products/services offered
    • 17.1.15.3 Recent developments
      • 17.1.15.3.1 Expansions
  • 17.1.16 LGC LIMITED
    • 17.1.16.1 Business overview
    • 17.1.16.2 Products/services offered
      • 17.1.16.2.1 Deals
  • 17.1.17 WUXI BIOLOGICS
    • 17.1.17.1 Business overview
    • 17.1.17.2 Products/services offered
  • 17.1.18 TECAN TRADING AG
    • 17.1.18.1 Business overview
    • 17.1.18.2 Products/services offered
      • 17.1.18.2.1 Deals
  • 17.1.19 TWIST BIOSCIENCES
    • 17.1.19.1 Business overview
    • 17.1.19.2 Products/services offered
    • 17.1.19.3 Recent developments
      • 17.1.19.3.1 Product launches
      • 17.1.19.3.2 Deals
  • 17.1.20 AZENTA US, INC.
    • 17.1.20.1 Business overview
    • 17.1.20.2 Products & services offered
    • 17.1.20.3 Recent developments
      • 17.1.20.3.1 Deals
• 17.2 OTHER PLAYERS
  • 17.2.1 MGI TECH CO. LTD.
  • 17.2.2 NOVOGENE CO., LTD.
  • 17.2.3 NEW ENGLAND BIOLABS
  • 17.2.4 GENSCRIPT
  • 17.2.5 PSOMAGEN
  • 17.2.6 ZYMO RESEARCH CORPORATION
  • 17.2.7 HAMILTON COMPANY
  • 17.2.8 NEOGENOMICS LABORATORIES
  • 17.2.9 FULGENT GENETICS
  • 17.2.10 SD BIOSENSOR, INC.

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS